DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Hydrolethalus — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHydrolethalus maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for hydrolethalus is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
pseudouridine synthase 3 (PUS3) — PUS3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9ENB · 2.66 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
Hydrolethalus syndrome was first described in Finland, where the incidence is approximately 1 in 20,000 and all Finnish patients were stillborn or died during the first day of life. The syndrome consists of hydrocephalus, polydactyly, micrognathia, midcranial malformations, visceral abnormalities, and perinatal lethality. A 1987 report described an infant with manifestations of the syndrome who survived for over 5 months; previously the longest survival reported had been 2 days. Only three non-Finnish cases had survived beyond the neonatal period before 2001.
In 2001 the first Oriental girl with a 'milder' form of hydrolethalus syndrome was reported. She died at age 44 days, making her the fourth reported case surviving beyond the neonatal period. A 1996 report described the first Hungarian patient, who displayed many signs of the syndrome but had no cleft lip and visceral abnormalities, suggesting the existence of an oligosymptomic form and that Dandy-Walker malformation with polydactyly may be a manifestation of the syndrome.
No drug treatments, interventions, or therapeutic trials appear in any of these reports. The literature consists entirely of case descriptions and differential diagnosis. Whether the spectrum from lethal to milder forms is due to allelism or locus heterogeneity remains unknown, and no molecular analysis has resolved this.
What is still missing is any molecular characterisation of the condition, any systematic natural history study with consistent diagnostic criteria, and any funding or trial design aimed at supportive care or prenatal intervention. Patient stratification by genotype is not possible until the genetic basis is established.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American Journal of Medical Genetics · 1987 · 33 citations
Hydrolethalus syndrome: Report of an apparent mild case, literature review, and differential diagnosis
AbstractWe present an infant with manifestations of the hydrolethalus syndrome who has survived for over 5 months; previously, the longest survival reported in this condition has been 2 days. The literature is reviewed and the clinical and pathological findings of our patient are compared with those of the 50 previously reported cases. The differential diagnosis of the condition is discussed.
Dandy‐Walker malformation and polydactyly: a possible expression of hydrolethalus syndrome
AbstractHydrolethalus syndrome consists of hydrocephalus, polydactyly, micrognathia, midcranial malformations, visceral abnormalities and perinatal lethality. It was first described in Finland, and only a few other cases outside Scandinavia are known. We report the first Hungarian patient who displayed many signs of the syndrome but had no cleft lip and visceral abnormalities. This observation suggests the existence of oligosymptomic hydrolethalus syndrome, and suggests that Dandy-Walker malformation with polydactyly may be a manifestation of the hydrolethalus syndrome.
An Asian girl with a ???milder??? form of the Hydrolethalus syndrome
AbstractHydrolethalus syndrome is an autosomal recessive disorder characterized by hydrocephalus, micrognathia, limb anomalies and several other abnormalities, mostly in the midline structures. The syndrome was first described in Finland, where the incidence is approximately 1 in 20000. All of the Finnish patients were stillborn or died during the first day of life. Only three non-Finnish cases have survived beyond the neonatal period. Here, we report the first Oriental girl with a 'milder' form of hydrolethalus syndrome. The patient died at age 44 days making her the fourth reported case surviving beyond the neonatal period. The case supports the concept of a 'milder' form of the syndrome. Whether this spectrum is due to allelism or locus heterogeneity awaits molecular analysis.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
